Virus Test Results - ViBac Technologies

To Whom IT May Concern:
Testing results:
This is to confirm that the anti-microbial
compound labeled as 2915-1916141125
has an efficacy of >99.99% percent on application to live virus.
Application of compound labeled 2915-191?141125 has a continued efficacy at
preventing the virus species from surviving on treated surface. Additionally compounds
2915-1916141125 and 2915-1916141-1612211960 have shown efficacy against
norovirus, rotavirus, adenovirus,and poliovirus which are listed in the latest EPA document
as surrogate species for success against Ebolavirus. (see attachment).
See results excerpted below.
TABLE I
Viral Recoveries lind LogjQ and Pereent Reductio ... Followh11 Exposure to Telt Product #1, Nonwoven
Treated Bille Material, and Test Product #3, Nonwoven Control Blue Material
Virus: Swine-lib Influenza A HI Nl strai n AJCalifolnlalO4t2(l09 (CDC #200(712041)
Hosl Coil Line: MOCK (ATCC IICCL-34)
Volume PJ.ted pet Woll: 1.0 rnL
Nonwoven Treated Blue Material
Replicate 3
Replicate I Replicate 2
Dilation
Plated
Nonwoven Control Blue Moteriol
Replicate I
Replicate 2
Replicate 3
Jnfl!al
Population
-2
CT
CT
CT
++++
++++
++++
NT
-3
+0++
0000
0000
++++
++++
+++ ...
++++
·4
++00
0000
0000
++++
++++
++++
++++
-s
0000
0000
0000
++++
++++
+++ ...
+H+
·6
0000
0000
0000
+++0
++00
++0+
++++
·7
NT
3.75
NT
NT
6.00
NT
6.25
H(}+
2.50
NT
6.2~
NT
2.50
rcnx,
7.2!
(log10)
Avctllgo
TCIO (loglo)
2.9;t
ii,17
Average
Loglo
reduction
4.;l3
).OS
Average
>99.99
91.68
Percent
Reduction
+ - ePE present
.
o -
CPE not detected
CT·
NT N/A-
Cytoloxlcity
Not tested
Not applicable
Dr. Ming
Ph.D (Baylor University)
Consulting Chemist.
NA
Interim Guidance for Environmental Infection Control in Hospitals for Ebola Virus:
On August 1, 2014, CDCreleased guidance titled,"lnfection
Prevention and Control
Recommendations for Hospitalized Patients with Known or Suspected Ebala Hemorrhagic
Fever in U.S. Hospitals."
•
• Use a U.S. Environmental Protection Agency (EPA)-registered hospital disinfectant with
a label claim for a non-enveloped virus [e.g., norovirus, rotavirus, adenovirus,
poliovirus) to disinfect environmental surfaces in rooms of patients with suspected
or confirmed Ebola virus infection. Although there are no products with specific
label claims against the Ebola virus, enveloped viruses such as Ebola are susceptible
to a broad range of hospital disinfectants used to disinfect hard, non-porous
surfaces. In contrast, non-enveloped viruses are more resistant to disinfectants. As a
precaution, selection of a disinfectant product with a higher potency than what is
normally required for an enveloped virus is being recommended at this time. EPAregistered hospital disinfectants with label claims against non-enveloped viruses
(e.g., norovirus, rotavirus, adenovirus, poliovirus) are broadly antiviral and capable of
inactivating both enveloped and non-enveloped viruses.
2